Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 289

1.

Cytochrome P450 pharmacogenetics and cancer.

Rodriguez-Antona C, Ingelman-Sundberg M.

Oncogene. 2006 Mar 13;25(11):1679-91. Review.

PMID:
16550168
2.

Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment.

Rodriguez-Antona C, Gomez A, Karlgren M, Sim SC, Ingelman-Sundberg M.

Hum Genet. 2010 Jan;127(1):1-17. doi: 10.1007/s00439-009-0748-0. Epub 2009 Oct 8. Review.

PMID:
19823875
3.

Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk.

Bozina N, Bradamante V, Lovrić M.

Arh Hig Rada Toksikol. 2009 Jun;60(2):217-42. doi: 10.2478/10004-1254-60-2009-1885. Review.

PMID:
19581216
4.

Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

van Schaik RH.

Invest New Drugs. 2005 Dec;23(6):513-22. Review.

PMID:
16267627
5.

Polymorphism of human cytochrome P450 enzymes and its clinical impact.

Zhou SF, Liu JP, Chowbay B.

Drug Metab Rev. 2009;41(2):89-295. doi: 10.1080/03602530902843483. Review.

PMID:
19514967
6.

Expression of cytochrome P450 in tumor tissues and its association with cancer development.

Oyama T, Kagawa N, Kunugita N, Kitagawa K, Ogawa M, Yamaguchi T, Suzuki R, Kinaga T, Yashima Y, Ozaki S, Isse T, Kim YD, Kim H, Kawamoto T.

Front Biosci. 2004 May 1;9:1967-76. Review.

PMID:
14977602
7.

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation.

Zanger UM, Turpeinen M, Klein K, Schwab M.

Anal Bioanal Chem. 2008 Nov;392(6):1093-108. doi: 10.1007/s00216-008-2291-6. Epub 2008 Aug 10. Review.

PMID:
18695978
8.

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.

Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C.

Pharmacol Ther. 2007 Dec;116(3):496-526. Epub 2007 Oct 9. Review.

PMID:
18001838
9.

Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Zhou SF.

Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. Review.

PMID:
19817501
10.

Genetic variability in susceptibility and response to toxicants.

Ingelman-Sundberg M.

Toxicol Lett. 2001 Mar 31;120(1-3):259-68. Review.

PMID:
11323184
11.

Cytochromes P450 and metabolism of xenobiotics.

Anzenbacher P, Anzenbacherová E.

Cell Mol Life Sci. 2001 May;58(5-6):737-47. Review.

PMID:
11437235
12.

Genetic polymorphism and toxicology--with emphasis on cytochrome p450.

Johansson I, Ingelman-Sundberg M.

Toxicol Sci. 2011 Mar;120(1):1-13. doi: 10.1093/toxsci/kfq374. Epub 2010 Dec 13. Review.

13.

Cytochrome P450 and anticancer drugs.

Fujita K.

Curr Drug Metab. 2006 Jan;7(1):23-37. Review.

PMID:
16454691
14.

Cytochromes P450: decision-making tools for personalized therapeutics.

Murray M, Petrovic N.

Curr Opin Mol Ther. 2006 Dec;8(6):480-6. Review.

PMID:
17243482
15.

[Polymorphism and the level of P450 gene expression in xenobiotic metabolism].

Niemira M, Wiśniewska A, Mazerska Z.

Postepy Biochem. 2009;55(3):279-89. Review. Polish.

PMID:
19928584
16.

Cancer pharmacogenomics: achievements in basic research.

Nakajima M, Yokoi T.

Int J Clin Oncol. 2005 Feb;10(1):14-9. Review.

PMID:
15729595
17.

CYP450 pharmacogenetics for personalizing cancer therapy.

van Schaik RH.

Drug Resist Updat. 2008 Jun;11(3):77-98. doi: 10.1016/j.drup.2008.03.002. Epub 2008 May 19. Review.

PMID:
18486526
19.

Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents.

van Schaik RH.

Ther Drug Monit. 2004 Apr;26(2):236-40. Review.

PMID:
15228172
20.

Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences.

Rodrigues AD, Rushmore TH.

Curr Drug Metab. 2002 Jun;3(3):289-309. Review. Erratum in: Curr Drug Metab. 2002 Oct;3(5):559..

PMID:
12083322
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk